Your session is about to expire
← Back to Search
Monoclonal Antibodies
Zanidatamab + Chemotherapy for Gastrointestinal Cancers
Phase 2
Waitlist Available
Research Sponsored by Zymeworks Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
BTC: Unresectable, locally advanced, recurrent or metastatic HER2-expressing BTC (including intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma [ECC], or gallbladder cancer [GBC]) (IHC 3+ with or without gene amplification; or IHC 0, 1+ or 2+ with gene amplification, based upon central assessment)
Adequate cardiac left ventricular function, as defined by a LVEF >/= institutional standard of normal
Must not have
Prior treatment with a HER2-targeted agent
Peripheral neuropathy > Grade 1 per NCI-CTCAE v5.0
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Summary
This trial is testing a new cancer drug, zanidatamab, to see if it is safe and effective for treating certain types of gastrointestinal cancers. Eligible patients have cancer that has spread and cannot be removed by surgery.
Who is the study for?
This trial is for adults with advanced HER2-expressing gastrointestinal cancers, including gastroesophageal adenocarcinoma, biliary tract cancer, and colorectal cancer that can't be removed by surgery. Participants should have an ECOG score of 0 or 1 (which means they are fully active or restricted in physically strenuous activity but can do light work), no prior treatment with HER2-targeted agents, and no significant heart disease or untreated brain metastases.
What is being tested?
The study tests ZW25 (zanidatamab) combined with standard chemotherapy to see how safe it is and how well it works against certain gastrointestinal cancers. It's a Phase 2 trial where all participants receive the experimental drug plus one of several chemo regimens like Fluorouracil/Leucovorin with Bevacizumab or Gemcitabine/Cisplatin.
What are the potential side effects?
Possible side effects include reactions related to infusion of the drugs, nausea, vomiting from chemotherapy; increased risk of bleeding or blood clots due to Bevacizumab; nerve damage symptoms like tingling or numbness from Oxaliplatin; and general fatigue.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My bile duct cancer is advanced and cannot be removed by surgery, and it tests positive for HER2.
Select...
My heart's left ventricle is functioning well.
Select...
My stomach cancer is advanced or has spread and tests show it is HER2 positive.
Select...
My colorectal cancer is advanced, cannot be surgically removed, and tests positive for HER2 without certain gene mutations.
Select...
My stomach cancer is advanced and cannot be removed by surgery, and it tests positive for HER2.
Select...
My cancer can be measured or observed.
Select...
I am fully active or can carry out light work.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been treated with a HER2-targeted therapy before.
Select...
My nerve damage does not severely affect my daily activities.
Select...
I do not have serious heart conditions or recent heart attacks.
Select...
I do not have any health conditions that prevent me from taking bevacizumab.
Select...
I don't have another cancer that could affect this treatment's safety or results.
Select...
I have a serious lung condition affecting the tissue and space around the air sacs.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of adverse events (Part 1)
Incidence of dose-limiting toxicities (DLTs) (Part 1)
Incidence of lab abnormalities (Part 1)
+1 moreSecondary study objectives
Clinical benefit rate (Parts 1 and 2)
Disease control rate (Parts 1 and 2)
Duration of response (Parts 1 and 2)
+6 moreTrial Design
5Treatment groups
Experimental Treatment
Group I: ZW25 + mFOLFOX6 with bevacizumabExperimental Treatment5 Interventions
ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab
Group II: ZW25 + mFOLFOX6Experimental Treatment4 Interventions
ZW25 plus 5-FU, leucovorin, and oxaliplatin
Group III: ZW25 + XELOXExperimental Treatment3 Interventions
ZW25 plus capecitabine and oxaliplatin
Group IV: ZW25 + FPExperimental Treatment3 Interventions
ZW25 plus fluorouracil (5-FU) and cisplatin
Group V: ZW25 + CisGemExperimental Treatment2 Interventions
ZW25 plus cisplatin and gemcitabine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
2013
Completed Phase 3
~3970
Cisplatin
2013
Completed Phase 3
~3120
Oxaliplatin
2011
Completed Phase 4
~2890
Bevacizumab
2013
Completed Phase 4
~5540
ZW25 (Zanidatamab)
2020
Completed Phase 2
~90
Fluorouracil
2014
Completed Phase 3
~11700
Leucovorin
2005
Completed Phase 4
~6010
Gemcitabine
2017
Completed Phase 3
~1920
Find a Location
Who is running the clinical trial?
Zymeworks Inc.Lead Sponsor
10 Previous Clinical Trials
2,398 Total Patients Enrolled
Jazz PharmaceuticalsLead Sponsor
249 Previous Clinical Trials
34,861 Total Patients Enrolled
Jonathan Grim, MD, PhDStudy DirectorZymeworks Inc.
1 Previous Clinical Trials
918 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been treated with a HER2-targeted therapy before.My condition meets the criteria outlined in Part 1.My bile duct cancer is advanced and cannot be removed by surgery, and it tests positive for HER2.I haven't had cancer treatment recently, except for early-stage therapy over 6 months ago.I have treated brain metastases and have been stable without steroids or seizure meds for 1 month.My heart's left ventricle is functioning well.My stomach cancer is advanced or has spread and tests show it is HER2 positive.My colorectal cancer is advanced, cannot be surgically removed, and tests positive for HER2 without certain gene mutations.My nerve damage does not severely affect my daily activities.My stomach cancer is advanced and cannot be removed by surgery, and it tests positive for HER2.I do not have serious heart conditions or recent heart attacks.I do not have any health conditions that prevent me from taking bevacizumab.I don't have another cancer that could affect this treatment's safety or results.My organs are working well.I have colorectal cancer and have had only one cycle of 5-FU-based chemotherapy.I have started treatment for advanced bile tract cancer but haven't completed more than one cycle of gemcitabine-based chemotherapy.I finished palliative radiotherapy at least 2 weeks ago.I have been diagnosed with a specific disease.I have a serious lung condition affecting the tissue and space around the air sacs.I do not have active hepatitis B or C, or if I have HIV, it is well controlled.This information is part of a larger set of criteria.This information is part of a multi-step process.My cancer can be measured or observed.I am fully active or can carry out light work.
Research Study Groups:
This trial has the following groups:- Group 1: ZW25 + mFOLFOX6 with bevacizumab
- Group 2: ZW25 + FP
- Group 3: ZW25 + mFOLFOX6
- Group 4: ZW25 + XELOX
- Group 5: ZW25 + CisGem
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger